TruBridge, Inc.
NASDAQ•TBRG
CEO: Mr. Christopher L. Fowler
セクター: Healthcare
業種: Medical - Healthcare Information Services
上場日: 2002-05-21
TruBridge, Inc. provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. The company operates in three segments: Revenue Cycle Management (RCM), Electronic Health Record (HER), and Patient Engagement. It focuses on providing RCM solutions for care settings, regardless of primary healthcare information solutions provider along with business management, consulting, managed IT services, and analytics and business intelligence. The company provides acute care solutions and related services for community hospitals, and physician clinics; and patient engagement and empowerment technology solutions to improve patient outcomes and engagement strategies with care providers. In addition, it offers patient liability estimates eligibility verification, claim scrubbing and submission, remittance management, denial/audit management, and contract management; and offers RCM services, such as accounts receivable management, private pay service, medical coding, revenue cycle consulting, and other additional insurance and patient billing services. Further, it offers consulting and business management services; managed IT services; encoder solutions; patient management; financial accounting; clinical; patient care; and enterprise applications. Additionally, it offers TruBridge HER platform, including total system support, national client conference, continuing education, software releases, hardware replacement, cloud electronic health record, forms and supplies, and public cloud infrastructure services; post-acute care software systems, and support and maintenance services; and InstantPHR, an interactive portal and CHBase which funnels data from multiple sources into one platform. The company was formerly known as Computer Programs and Systems, Inc. and changed its name to TruBridge, Inc. in March 2024. TruBridge, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.
連絡先情報
時価総額
$292.68M
PER (TTM)
50.6
53.9
配当利回り
--
52週高値
$32.00
52週安値
$17.86
52週レンジ
順位42Top 47.5%
3.9
F-Score
改良版 Piotroski 分析
9年ファンダメンタル
弱い • 3.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2017-2025
財務ダッシュボード
Q3 2025 データ
売上高
$86.11M+2.71%
直近4四半期の推移
EPS
$0.37-17.78%
直近4四半期の推移
フリーCF
$13.65M+184.67%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Nine Months Net Income Swing Net income $8.6M for nine months 2025, reversing prior $15.4M loss; operating income $15.9M versus $76K.
Revenue Growth Across Segments Total revenues reached $259.0M, up 2% for nine months; Patient Care revenue increased 3% to $94.1M.
Strong Operating Cash Flow Cash provided by operations totaled $28.1M for nine months 2025, a $6.3M increase over prior period results.
Patient Care EBITDA Surge Patient Care Adjusted EBITDA grew 56% to $21.0M for nine months 2025, driven by installation and SaaS revenue.
リスク要因
Material Weakness Persists Management concluded material weakness in revenue control design continued through September 30, 2025; remediation underway.
Healthcare Regulatory Uncertainty New OBBBA legislation signed July 2025 creates uncertainty impacting hospital clients' capital allocation and reimbursement funding.
VG Sellers Earnout Dispute Received arbitration request regarding Viewgol earnout provisions; potential litigation exposure currently unestimable liability.
Increased Stock Compensation Costs Net stock-based compensation expense rose to $5.1M for nine months 2025, an increase of $2.2M versus prior year period.
見通し
Core Growth Strategy Focus Strategy centers on cross-selling Financial Health services into existing Patient Care customer base for long-term growth.
AI Prediction Model Launch Planning first generative AI denials prediction model release to public during first quarter of 2026.
Bookings Reporting Transition Transitioning to Annual Contract Value (ACV) bookings methodology starting January 2025 for better comparability.
Liquidity Position Remains Strong Cash and borrowing capacity provide adequate resources to fund ongoing requirements for next twelve months and beyond.
同業比較
売上高 (TTM)
HITI$424.09M
$349.88M
LFMD$252.34M
粗利益率 (最新四半期)
LFMD87.7%
84.9%
78.3%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CERS | $430.28M | -26.9 | -27.9% | 45.6% |
| SOPH | $321.60M | -4.3 | -93.9% | 38.8% |
| SENS | $306.85M | -5.2 | -135.2% | 29.4% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-1.8%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年3月9日
EPS:$0.41
|売上高:-
財務レポート
財務データ
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年11月7日|売上高: $86.11M+2.7%|EPS: $0.37-17.8%予想を下回るForm 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年8月8日|売上高: $85.73M+0.2%|EPS: $0.17-158.6%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年5月9日|売上高: $87.21M+3.7%|EPS: $0.03-118.1%予想を下回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年3月17日|売上高: $342.65M+0.9%|EPS: $-1.38+56.2%予想を下回るForm 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年11月12日|売上高: $83.83M+1.4%|EPS: $0.45-287.5%予想を上回るForm 10-Q/A - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年8月14日|売上高: $84.12M-2.5%|EPS: $-0.17-181.0%予想を上回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月14日|売上高: $85.60M+1.2%|EPS: $-0.29+45.0%予想を下回るForm 10-K/A - FY 2023
会計期末: 2023年12月31日|提出日: 2024年8月14日|売上高: $339.44M+3.9%|EPS: $-3.15-391.7%予想を下回る